Latest court orders, judgments, and legal developments from Indian courts — AI-curated and summarized.
This week’s IP developments include judicial rulings on pharmaceutical patents, copyright, and AI use in filings. Also features a free online patent treatise and international treaty updates affecting Indian IP practice.
IPO's 2026 Draft Guidelines for Pharma Patents contain misquotations and misinterpretations, say experts. Flawed approach risks disrupting patent examination standards.
The IPO’s Draft Guidelines for Examination of Pharmaceutical Patent Applications, 2026 face severe criticism for misquoting provisions and misinterpreting patentability standards, raising concerns over examination consistency and legal accuracy.
The IPO's Draft Guidelines for Examination of Pharmaceutical Patent Applications (2026) face criticism for misquoting statutes and introducing inconsistent standards, prompting calls for comprehensive revision before finalisation.
The IPO’s 2026 Draft Guidelines face strong critique for misquoting law and risking disruption to patent prosecution in pharmaceuticals; calls grow for immediate revision.